/PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic...

YolTech Therapeutics has successfully raised $45 million in Series B funding, led by AstraZeneca-CICC, to progress its innovative gene-editing therapies.

YolTech Therapeutics shares encouraging data on YOLT-203, an innovative gene-editing treatment for Primary Hyperoxaluria Type 1, showcasing safety and efficacy.

YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.

SHANGHAI, June 5, 2025 /PRNewswire/ — YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). “The FDA …

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive races.

YolTech Therapeutics reveals positive interim findings from a trial on YOLT-101, an innovative treatment for familial hypercholesterolemia that significantly lowers cholesterol levels.

There is panic among Western biotech that Chinese competitors will eat their lunch with their capital-efficient fast-follower strategy which...

YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.

YolTech Therapeutics has received FDA approval for YOLT-101, a groundbreaking gene-editing therapy aimed at treating familial hypercholesterolemia, marking a pivotal moment in biotechnology.

YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences demonstrates encouraging initial clinical data for...

YolTech Therapeutics has achieved significant FDA designations for its gene therapy YOLT-203, aimed at treating primary hyperoxaluria type 1, promising hope for affected patients.

YolTech Therapeutics has successfully completed the dose escalation phase in its Phase I/IIa trial for YOLT-201, a groundbreaking CRISPR/Cas9 gene-editing treatment for ATTR amyloidosis.

YolTech Therapeutics embarks on a significant clinical trial for YOLT-204, an innovative gene therapy targeting β-thalassemia, aiming for curative outcomes.